CytomX Therapeutics (CTMX) EBITDA Margin (2014 - 2026)
CytomX Therapeutics' EBITDA Margin came in at -1673.77% for Q2 2026, down 1668.73 percentage points from -5.03% a year earlier and down 1484.44 percentage points from the prior quarter.
Powered by 
Analysis
CytomX Therapeutics (CTMX) EBITDA Margin (2014 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, CytomX Therapeutics reported EBITDA Margin of -471.05%, down 502.73 percentage points year-over-year; for FY2025, it came in at -27.54%, down 46.92 percentage points from FY2024.
- EBITDA Margin carries a five-year change of +86.40 percentage points (FY2020 to FY2025).
- Going back by year, EBITDA Margin was 19.38% in FY2024 (+23.64 pp), -4.26% in FY2023 (+181.76 pp), -186.02% in FY2022 (+117.74 pp) and -303.75% in FY2021 (-189.81 pp).
- The five-year range for quarterly EBITDA Margin is -4136.05% (Q4 2025) to 47.49% (Q4 2024).
- Year-over-year, EBITDA Margin has declined for four consecutive quarters, with an average year-over-year change of -783.99 percentage points over the last eight quarters.
- The fastest year-over-year change in EBITDA Margin over five years came in Q1 2023 (a gain of 326.48 percentage points), and the weakest in Q4 2025 (a drop of 4183.54 percentage points).
- Business Quant data shows CTMX's EBITDA Margin at -189.33% (Q1 2026), -4136.05% (Q4 2025) and -262.18% (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | CytomX Therapeutics | 586.15 Mn | -371.52 Mn | - | -1,673.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,673.77% |
| Mar 31, 2026 | -189.33% |
| Dec 31, 2025 | -4,136.05% |
| Sep 30, 2025 | -262.18% |
| Jun 30, 2025 | -5.03% |
| Mar 31, 2025 | 45.18% |
| Dec 31, 2024 | 47.49% |
| Sep 30, 2024 | 13.58% |
| Jun 30, 2024 | -31.83% |
| Mar 31, 2024 | 29.24% |
| Dec 31, 2023 | -0.45% |
| Sep 30, 2023 | 13.67% |
| Jun 30, 2023 | -11.07% |
| Mar 31, 2023 | -21.52% |
| Dec 31, 2022 | -44.23% |
| Sep 30, 2022 | -260.94% |
| Jun 30, 2022 | -229.08% |
| Mar 31, 2022 | -348.01% |
| Dec 31, 2021 | -307.47% |
| Sep 30, 2021 | -330.38% |
API Access
CytomX Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CTMX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "CTMX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CTMX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();